Ameriprise
CGEM icon

Ameriprise’s Cullinan Oncology CGEM Stock Holding History

Ameriprise’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-56,777
Closed -$337K – 4097
2025
Q3 		$337K Buy
56,777
+11,485
+25% +$84.1K ﹤0.01% 3762
2025
Q2 		$341K Buy
+45,292
New +$364K ﹤0.01% 3656
2025
Q1 		– Sell
-504,264
Closed -$6.14M – 4036
2024
Q4 		$6.14M Buy
504,264
+86,756
+21% +$1.25M ﹤0.01% 2210
2024
Q3 		$6.99M Buy
417,508
+13,630
+3% +$242K ﹤0.01% 2130
2024
Q2 		$7.04M Sell
403,878
-16,339
-4% -$348K ﹤0.01% 2026
2024
Q1 		$7.16M Buy
420,217
+365,296
+665% +$5.64M ﹤0.01% 2083
2023
Q4 		$560K Sell
54,921
-7,687
-12% -$68.1K ﹤0.01% 3417
2023
Q3 		$567K Sell
62,608
-258
-0.4% -$2.69K ﹤0.01% 3357
2023
Q2 		$676K Buy
62,866
+3,034
+5% +$32.2K ﹤0.01% 3327
2023
Q1 		$612K Hold
59,832
– – ﹤0.01% 3349
2022
Q4 		$631K Buy
+59,832
New +$727K ﹤0.01% 3316

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Ameriprise's CGEM Position: Q4 2025 in Review

Ameriprise sold out of Cullinan Oncology (CGEM) in Q4 2025, closing a stake of 56,777 shares — an estimated $337K sold.

Ameriprise first reported a position in CGEM in Q4 2022 and held it in 11 quarters. The position peaked at $7.16M in Q1 2024. 153 funds tracked by Wall St. Rank hold CGEM as of Q4 2025.

  • Ameriprise reported no remaining Cullinan Oncology position as of Q4 2025 after selling out during the quarter.
  • Ameriprise sold 56,777 Cullinan Oncology shares in Q4 2025, an estimated $337K.
  • Ameriprise first reported a position in Cullinan Oncology in Q4 2022 and held it in 11 quarters.
  • Ameriprise's Cullinan Oncology position peaked at $7.16M in Q1 2024.
  • 153 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.